Key Takeaways
- • Johnson & Johnson agreed to acquire Ollin Biosciences for $2.2 billion, comprising a $1.2 billion upfront payment and up to $1.1 billion in additional milestone payments tied to OLN324.
- • OLN324, a bispecific antibody blocking VEGF and Ang2, is positioned as a potential competitor to Roche's Vabysmo, which targets the same pathways and is approved for wet AMD and DME.
- • In a Phase 1b head-to-head proof-of-concept study, Ollin reported OLN324 produced faster and greater structural eye changes and numerically better vision improvement at 20 weeks versus Vabysmo in AMD and DME.
- • Blackstone Life Sciences separately agreed to pay up to $750 million for OLN324's late-stage development in exchange for regulatory and sales milestones and royalties on an approved product.
- • The deal adds OLN102, a bispecific antibody for thyroid eye disorder, and the transaction is expected to close by the end of 2026.
Summary
The lead asset, OLN324, is a bispecific antibody designed to block VEGF and Ang2, the same targets addressed by Vabysmo. In a proof-of-concept Phase 1b study presented in July at the annual meeting of the American Society of Retina Specialists, Ollin reported that OLN324, administered by intraocular injection, produced faster and greater structural changes in the eye and numerically better vision improvement at 20 weeks compared with Vabysmo in both age-related macular degeneration and diabetic macular edema, the two indications for which Vabysmo is approved. Kip Connor, vice president and ophthalmology disease area stronghold leader at J&J, said the data were "compelling" and point to a "potentially transformative clinical profile." Ollin has claimed the drug could be best in class, though these results come from an early-stage study.
J&J will assume responsibility for the pivotal Phase 3 trials of OLN324 in wet AMD and DME, for which trial financing has already been arranged. Separately, Blackstone Life Sciences agreed to pay up to $750 million toward OLN324's late-stage clinical development in return for regulatory and sales milestone payments and royalties on any approved product.
Ollin was formed in 2023 and formally launched last year with $100 million in financing led by Arch Venture Partners, Mubadala Capital and Monograph Capital. OLN324 was discovered by China-based Innovent Biologics, which collaborated with Ollin on clinical development. In June, TCGX and Arch co-led a $330 million Series B round to support the Phase 3 program. The acquisition also brings OLN102, a bispecific antibody targeting TSHR and IGF-1R for thyroid eye disorder, which was discovered by VelaVigo and was slated to enter the clinic this year. The companies expect the transaction to close by the end of 2026.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.